Local News: Kingdom City, MO 

 | 

Sign Up

 | 

Sign In

Advertisment

Genzyme General

Genzyme General News Editors

RoboBlogger

I edit this news page on Topix when no humans are available to help.

People just like you make Genzyme General News on Topix better every day. If you're interested in becoming an editor, apply today!

Edits History | Editor Blog

RSS icon mobile icon

Genzyme General News

News on Genzyme General continually updated from thousands of sources around the net.

Yesterday | SmartMoney

3 Stocks Poised for Soaring 2010 Profits

Each company's shares sell for well more than 20 times this year's earnings estimate.

Comment?

Related Topix: Financial Markets, Biotech, Medicine, Healthcare Industry

Sun Dec 13, 2009

The Biotech Stock Blog

Genoptix: Fundamentals and Shorts Protect Against Long and Short Term Downside Risks

It's rare to find companies where extreme growth is complemented with trading multiples near its competitors.

Comment?

Related Topix: Biotech, BioReference Laboratories, Healthcare Industry, Quest Diagnostics

Fri Dec 11, 2009

American Chronicle

News and FDA Updates for Fero

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Comment?

Related Topix: Healthcare Law, Law, Food and Drug Administration, Biotech, Medicine, Forest Labs, Healthcare Industry, Opinion

Thu Dec 10, 2009

MarketNewsVideo

Downgrades: Genzyme, Aeropostale

This morning, investment firm Collins Stewart downgraded shares of Genzyme from Buy to Hold as the viral re-contamination risk remains high.

Comment?

Related Topix: Biotech, Retail, Medicine, Apparel, Aeropostale, Healthcare Industry, Business News, Video

Wed Dec 09, 2009

Pharmaceutical Processing

Genzyme Laboratory Recognized for Quality

Genzyme Corporation announced today that its genetic testing laboratory located in Phoenix, Arizona, has obtained the CAP 15189SM Accreditation to the International Standards Organization 15189:2007 Standard for laboratories from the College of American Pathologists.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Phoenix, AZ, Phoenix Metro, Pathology

Tue Dec 08, 2009

Drugs.com

Genzyme's Mozobil Shows Promise in Chemosensitization

Dec 8, 2009 - Genzyme Corporation announced today that a Phase 1/2 trial provided early clinical data suggesting that Mozobil in combination with chemotherapy may offer a therapeutic impact on leukemic cells protected in bone marrow.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cancer, Health, St. Louis, MO, Leukemia

Mon Dec 07, 2009

Drugs.com

Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL

Dec 7, 2009 - Genzyme Corporation announced data from its CAM314 randomized Phase 3 clinical trial comparing Campath in combination with Fludara to Fludara alone in patients with relapsed and refractory chronic lymphocytic leukemia demonstrated that the FluCAM regimen significantly reduced the risk of disease progression or death compared to ...

Comment?

Related Topix: Fludara, Fludarabine Phosphate (generic), Medicine, Medication, Biotech, Healthcare Industry, New Orleans, LA

Myrtle Beach Online

Celgene buying Gloucester Pharma for $640 million

Biotechnology company Celgene Corp. said Monday it will buy privately held Gloucester Pharmaceuticals Inc.

Comment?

Related Topix: Biotech, Celgene, Medicine, Healthcare Industry, Science / Technology, Food and Drug Administration, Lymphoma, Health, Pfizer

Sun Dec 06, 2009

Seeking Alpha

Genzyme: Positive Development on the Lumizyme Front

Thursday morning, Genzyme announced that it had met with the FDA regarding the regulatory path forward for approval of Pompe disease drug Lumizyme.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

The Motley Fool

Better Biotech Buy: Celgene or Genzyme?

In a new Motley Fool series, we pit two stocks against each other on five criteria to determine the better buy.

Comment?

Related Topix: Biotech, Celgene, Medicine, Healthcare Industry, Financial Markets

Sat Dec 05, 2009

The Boston Globe

Genzyme plans to boost druga s production

One analyst said he was encouraged by Genzyme's new approach. Genzyme Corp. yesterday said it has scrapped its application to produce Lumizyme, a drug to treat the rare genetic disorder Pompe disease, in midsize bioreactors and instead will pursue a new pathway toward making the drug on a larger scale.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Food and Drug Administration, Boston, MA

Fri Dec 04, 2009

Barron's

Genzyme Held Back by Supply Problems

Hapoalim initiated coverage of the drug maker at Hold. Genzyme By Hapoalim Securities WE ARE INITIATING COVERAGE on Genzyme with a Hold rating and a 12-month target price of $55. Genzyme's franchise drug, Cerezyme , has been an unchallenged blockbuster for several years.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Cerezyme, Imiglucerase (generic), Medication

Mass High Tech

Genzyme opens access to former FDA-rejected Pompe disease drug

Genzyme Corp. has reopened enrollment in its Alglucosidase Alfa Temporary Access Program for adults suffering from Pompe disease to obtain access to the company's Lumizyme drug treatment prior to its approval for commercialization.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Food and Drug Administration

Thu Dec 03, 2009

Freshnews

Genzyme to Reopen Enrollment in Alglucosidase Alfa Temporary Access Program

Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program , a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme .

Comment?

Related Topix: Biotech, Healthcare Industry

Mass High Tech

Genzyme CEO Termeer sells $10M in shares

Henri Termeer, the CEO of Genzyme Corp. sold $10 million in shares at $50.47 on November 23.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Wed Dec 02, 2009

Waterford Today

Frontpage News

Genzyme Ireland named LifeSciences Company of the Year Genzyme Ireland named LifeSciences Company of the Year at Export Industry Awards Genzyme Ireland, the biotechnology company that employs over 450 people in Waterford, has been named Life Sciences Company of the Year at the Irish Exporters Association's Export Industry Awards 2009.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

The Boston Globe

Pfizer deal poses challenge for Cambridge-based Genzyme

Drug giant Pfizer Inc. , mounting a direct challenge to Cambridge biotech Genzyme Corp.

Comment?

Related Topix: Pfizer, Biotech, Medicine, Healthcare Industry, Boston, MA

Tue Dec 01, 2009

Http

Genzyme Begins Shipping From Troubled Allston Plant

Cambridge-based Genzyme Corp. said it has begun shipping new vials of its Cerezyme drug manufactured at the Allston plant shut down earlier this year because of contamination.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Mon Nov 30, 2009

BNET

Genzyme's Termeer Sells $10M in Stock Despite Company's Woes

Termeer's windfall occurred despite the following: It's not the first set of options that Termeer has cashed out.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Fri Nov 27, 2009

Health Care Renewal

Was is "Worst Biotech CEO" Worth?

Recently, we posted about misadventures of the leadership of biotechnology giant Genzyme.

Comment?

Related Topix: Biotech, Science / Technology, Medicine, Healthcare Industry, TheStreetcom, Media, Computers, Boston, MA

Kingdom City Jobs

Also on Topix